10.4 Collaborative Drug Therapy Management

Collaborative Drug Therapy Management

Massachusetts gives collaborative practice its own chapter of the Board's regulations: 247 CMR 16.00, Collaborative Drug Therapy Management. Candidates who look for it inside the professional practice standards chapter will not find it.

---

What Collaborative Drug Therapy Management Is

Under a collaborative drug therapy management (CDTM) agreement, a supervising physician delegates to a pharmacist the authority to manage a patient's drug therapy within a written protocol. Depending on the protocol, management can include:

• initiating drug therapy;
• modifying a dose, dosage form, route, frequency or duration;
• ordering and interpreting laboratory tests relevant to the therapy being managed;
• monitoring the patient's response and adverse effects; and
• discontinuing therapy.

The defining feature is that the pharmacist is exercising clinical judgement about the patient's therapy, not simply dispensing what someone else decided.

---

CDTM Is Not a Standing Order

These two mechanisms are constantly confused, and telling them apart is a reliable exam point.

[!IMPORTANT] The question to ask is whether the pharmacist is managing therapy or dispensing a product. A pharmacist who adjusts a warfarin dose based on an INR is doing CDTM. A pharmacist who hands out naloxone to a member of the public is acting on a standing order. The first requires an agreement naming that pharmacist; the second does not.

---

Structure of an Agreement

Collaborative practice regulation across jurisdictions consistently requires an agreement to be written, to identify the parties, to define the scope with precision, and to be reviewed periodically. In practice an agreement addresses:

• the identity and credentials of the collaborating practitioner and pharmacist;
• the patients or conditions covered;
• the drugs or drug categories covered and any excluded categories;
• the specific functions delegated, and their limits;
• the documentation the pharmacist must make and where it goes in the medical record;
• the communication required back to the practitioner, and its timing;
• the circumstances requiring referral back to the practitioner; and
• the review, renewal and termination arrangements.

[!WARNING] Read the current regulation for the specifics. The required content of an agreement, the approval or filing route, any pharmacist experience or training prerequisites, the permitted settings, and the record retention period are all set by the current text of 247 CMR 16.00 and the Board's policies, and Massachusetts has revised its collaborative practice framework more than once. Do not carry forward a specific figure from a commercial study aid; verify it against the regulation as it stands when you sit the exam.

---

What CDTM Does Not Change

A collaborative agreement expands what a pharmacist may do. It does not move any boundary elsewhere:

• Technicians are unaffected. 247 CMR 8.02(6)(d) and 8.04(4)(e) prohibit every technician tier from administering medications or vaccines, performing drug utilization review, conducting clinical conflict resolution, contacting prescribers about therapy clarification or modification, counselling patients, and performing final dispensing process validation. No agreement can delegate those to a technician.
• Registration still applies. A pharmacist managing therapy under an agreement is still working within a licensed pharmacy subject to 247 CMR, and any controlled substance involved still engages the MCSR, PMP and c. 94C requirements.
• Documentation still applies. Pharmacy records are retained for at least two years under 247 CMR 9.05, and CDTM documentation belongs in both the pharmacy record and the patient's medical record as the agreement specifies.
• The supervisory ratios still apply. A pharmacist running a CDTM clinic is still the pharmacist for ratio purposes under 247 CMR 8.06(3).

---

Continuing Education

There is no CDTM-specific continuing education allocation in 247 CMR 4.03. The annual requirements that do attach to particular activities are sterile compounding (5 hours), complex non-sterile compounding (3 hours) and pharmacy law (2 hours), plus 1 hour on immunizations per two-year cycle for those who oversee or administer vaccines. A pharmacist practising under a collaborative agreement should nonetheless expect the agreement itself to specify competence requirements.

---

Worked Traps

• A pharmacist not named in the agreement adjusts a dose under a colleague's CDTM protocol. Not authorised — CDTM authority runs to the pharmacists party to the agreement, unlike a standing order.
• A certified pharmacy technician telephones a physician to propose a dose change under the clinic protocol. Violation — contacting a prescriber about therapy modification is prohibited to technicians regardless of any agreement.
• A pharmacist relies on a five-year-old summary of Massachusetts collaborative practice requirements. Risky — verify against the current 247 CMR 16.00.